Directory Tag cannabis news
cannabis news
Williamsville, NY United States
14221
22nd Century Group, Inc., a plant biotechnology company, provides technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. It offers premium cigarettes under the RED SUN and MAGIC brands; and SPECTRUM, a line of research cigarettes for use in independent clinical studies. The company’s products under development include BRAND A, a very low nicotine cigarette; X-22, a tobacco-based botanical medical product for use as an aid to smoking cessation; and BRAND B, a low-tar-to-nicotine ratio cigarette. In addition, it engages in contract manufacturing business for third-party branded tobacco products. The company has scientific collaborations with the University of Virginia and Anandia Laboratories, Inc. to develop proprietary hemp strains with less than 0.3% dry weight content of delta-9-tetrahydrocannabinol. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Williamsville, New York.
[stock_market_widget type=”chart” symbol=”XXII” chart=”line” range=”1y” interval=”1mo” line-color=”rgb(49, 125, 189)”]
Napanee, ON Canada
K7R 3L2
ABcann Global Corporation manufactures and distributes medical cannabis. The company is headquartered in Napanee, Canada.
[stock_market_widget type=”chart” symbol=”ABCCF” chart=”line” range=”1y” interval=”1mo” line-color=”rgb(49, 125, 189)”]
Suite 103
Leamington, ON Canada
N8H 1N8
Aphria Inc. produces, supplies, and sells medical cannabis in Canada. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It also provides support services in the form of medical consultations, group therapies, and rehabilitation to veteran and first responders. The company sells its products through its online store or phones, as well as engages in the wholesale shipping of medical marijuana plant cuttings and dried buds to other licensed producers. Aphria Inc. is headquartered in Leamington, Canada.
[stock_market_widget type=”chart” symbol=”APH.TO” chart=”line” range=”1y” interval=”1mo” line-color=”rgb(49, 125, 189)”]
Suite 8, Level 2 57 Shenton Avenue
Joondalup, WA Australia
6027
AusCann Group Holdings Ltd researches, develops, cultivates, produces, and sells clinically validated cannabis medicines to patients in Australia. The company has a strategic partnership with Tasmanian Alkaloids Pty Ltd. AusCann Group Holdings Ltd is based in Joondalup, Australia.
[stock_market_widget type=”chart” symbol=”ACNNF” chart=”line” range=”1y” interval=”1mo” line-color=”rgb(49, 125, 189)”]
Suite 002
Toronto, ON Canada
M6J 0C2
Cannabis Wheaton Income Corp. operates as a cannabis streaming company. It provides funding for cannabis facility expansions, operations, and initial construction in exchange for minority equity interests and a portion of the cultivation production. The company was formerly known as Knightswood Financial Corp. and changed its name to Cannabis Wheaton Income Corp. in May 2017. Cannabis Wheaton Income Corp. was incorporated in 1987 and is based in Toronto, Canada.
[stock_market_widget type=”chart” symbol=”CBWTF” chart=”line” range=”1y” interval=”1mo” line-color=”rgb(49, 125, 189)”]
Suite 610 33 Preston Street
Ottawa, ON Canada
K1S 5N4
CannaRoyalty Corp.is a private equity firm specializing in acquisitions. The firm invests in the legal cannabis sector with a focus on research and intellectual property, consumer brands, and industry infrastructure. It seeks to invest in the United States and Canada. CannaRoyalty Corp. is headquartered in Ottawa, Canada.
[stock_market_widget type=”chart” symbol=”CNNRF” chart=”line” range=”1y” interval=”1mo” line-color=”rgb(49, 125, 189)”]
Unit 1 3280 Langstaff Road
Vaughan, ON Canada
L4K 5B6
CannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company was incorporated in 2015 and is headquartered in Vaughan, Canada.
[stock_market_widget type=”chart” symbol=”CNTTF” chart=”line” range=”1y” interval=”1mo” line-color=”rgb(49, 125, 189)”]
9th Floor 107 Elm Street
Stamford, CT United States
06902
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with chronic kidney disease associated pruritus undergoing hemodialysis, as well as in Phase II/III clinical trial for the treatment of dialysis patients suffering from uremic pruritus. The company is also developing Oral KORSUVA (CR845/difelikefalin) that has completed Phase I clinical trial to treat uremic pruritus; and in Phase I clinical trial to treat pruritus chronic kidney disease, as well as in Phase I clinical trial for treating pruritus chronic liver disease. In addition, it is developing CR845/difelikefalin Injection, which is in Phase III clinical trial for the treatment of acute post-operative pain; and Oral CR845/difelikefalin that has completed Phase IIb for treating chronic pain, as well as CR701, which is in preclinical trial for the treatment of chronic pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
[stock_market_widget type=”chart” symbol=”CARA” chart=”line” range=”1y” interval=”1mo” line-color=”rgb(49, 125, 189)”]
Second Floor
Norwood, MA United States
02062
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company’s lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in clinical studies in systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.
[stock_market_widget type=”chart” symbol=”CRBP” chart=”line” range=”1y” interval=”1mo” line-color=”rgb(49, 125, 189)”]
Suite 320
Toronto, ON Canada
M5V 2T3
Cronos Group Inc., formerly known as PharmaCan Capital Corp., is a principal investment firm. The firm seeks to invest in companies either licensed, or actively seeking a license, to produce medical marijuana pursuant to Canada’s Marijuana for Medical Purposes Regulations (MMPR). The firm typically invests in companies based in Canada. The firm is primarily an equity investor, may also advance debt as appropriate. It seeks to make minority investments with appropriate governance and shareholder rights. The firm seeks board representation consistent with the size of the investment, but does not need control. Cronos Group Inc. was incorporated in January, 2013 and is based in Toronto, Canada with an additional office in in Toronto, Canada.
[stock_market_widget type=”chart” symbol=”CRON” chart=”line” range=”1y” interval=”1mo” line-color=”rgb(49, 125, 189)”]